Industry News
Biotechnology Industry News
Athira drama not over yet, as investor and ally of former CEO calls for another C-suite change
Athira drama not over yet, as investor and ally of former CEO calls for another C-suite change aarmstrong Wed, 03/30/2022 - 13:19
GSK, CureVac hope 2nd time’s the charm as updated COVID vax launches into clinic
GSK, CureVac hope 2nd time's the charm as updated COVID vax launches into clinic mbayer Wed, 03/30/2022 - 10:45
Top Ginkgo execs each nab $364M pay packages thanks to 2021 SPAC deal
Top Ginkgo execs each nab $364M pay packages thanks to 2021 SPAC deal aarmstrong Wed, 03/30/2022 - 09:59
UPDATE: Top Ginkgo execs each nab $364M pay packages thanks to 2021 SPAC deal
UPDATE: Top Ginkgo execs each nab $364M pay packages thanks to 2021 SPAC deal aarmstrong Wed, 03/30/2022 - 09:59
Adagio knows its COVID-19 antibody works against old variants. Can it win EUA in the era of omicron?
Adagio knows its COVID-19 antibody works against old variants. Can it win EUA in the era of omicron? ntaylor Wed, 03/30/2022 - 08:03
Roche’s lung cancer gamble flames out as TIGIT digits come up short in phase 3
Roche's lung cancer gamble flames out as TIGIT digits come up short in phase 3 ntaylor Wed, 03/30/2022 - 05:10
Karyopharm hoping for some Keytruda stardust as former Merck & Co. exec joins as CMO
Karyopharm hoping for some Keytruda stardust as former Merck & Co. exec joins as CMO gmasson Tue, 03/29/2022 - 13:27
Outgoing NIAID vaccine R&D chief John Mascola reflects on leading ‘NASA-type incubator’
Outgoing NIAID vaccine R&D chief John Mascola reflects on leading 'NASA-type incubator' mbayer Tue, 03/29/2022 - 11:45
Cuts to the Bone: Orthopedic biotech slashes C-suite, overhauls entire pipeline
Cuts to the Bone: Orthopedic biotech slashes C-suite, overhauls entire pipeline mbayer Tue, 03/29/2022 - 10:26
Neuron23 snags $100M and a new Parkinson’s disease candidate
Neuron23 snags $100M and a new Parkinson's disease candidate ssorensen Tue, 03/29/2022 - 10:19
ImmunoGen files ovarian cancer ADC with FDA, a week after scaring investors with iffy survival data
ImmunoGen files ovarian cancer ADC with FDA, a week after scaring investors with iffy survival data aarmstrong Tue, 03/29/2022 - 09:34
Pfizer’s $7B ulcerative colitis drug racks up another phase 3 win, laying the groundwork for approval filings
Pfizer's $7B ulcerative colitis drug racks up another phase 3 win, laying the groundwork for approval filings ntaylor Tue, 03/29/2022 - 08:08
Sanofi pulls IGM into dealmaking whirlwind, paying $150M upfront to form 6-target R&D pact
Sanofi pulls IGM into dealmaking whirlwind, paying $150M upfront to form 6-target R&D pact ntaylor Tue, 03/29/2022 - 05:58
Biden seeks $2.1B funding boost for FDA, part of pan-agency pandemic preparedness plan
Biden seeks $2.1B funding boost for FDA, part of pan-agency pandemic preparedness plan aarmstrong Mon, 03/28/2022 - 14:26
Amylyx to answer for single-study ALS application at FDA advisory panel
Amylyx to answer for single-study ALS application at FDA advisory panel aarmstrong Mon, 03/28/2022 - 10:47
Another Biogen-Ionis collab hits the dust after phase 1 ALS flop
Another Biogen-Ionis collab hits the dust after phase 1 ALS flop mbayer Mon, 03/28/2022 - 10:38
Verastem takes on debt to get RAS tumor program to finish line
Verastem takes on debt to get RAS tumor program to finish line ntaylor Mon, 03/28/2022 - 08:17
Lilly, after making $1B bet, posts ‘compelling’ late-phase data on Dupixent rival
Lilly, after making $1B bet, posts 'compelling' late-phase data on Dupixent rival ntaylor Mon, 03/28/2022 - 06:12
Icosavax’s COVID-19 shot fails to deliver in early data, spurring debate about ‘fatal flaw’ in platform
Icosavax's COVID-19 shot fails to deliver in early data, spurring debate about 'fatal flaw' in platform mbayer Fri, 03/25/2022 - 10:18
89bio gains a little more confidence in NASH treatment with new hormone data
89bio gains a little more confidence in NASH treatment with new hormone data aarmstrong Fri, 03/25/2022 - 09:54